Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Jazz Pharmaceuticals plc JAZZ

Healthcare Biotechnology
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Xyrem for the treatment of cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut syndrome... see more

Current News (NDAQ:JAZZ)

Jazz Pharmaceuticals to Present Extensive New Data and Real-World Evidence Highlighting Epidiolex® (cannabidiol) Outcomes in Treatment-Resistant Epilepsies at the American Epilepsy Society 2025 Annual Meeting

PR Newswire December 5, 2025

Jazz Pharmaceuticals to Present Pivotal Phase 3 Results of Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma at the 2026 ASCO Gastrointestinal Cancers Symposium

PR Newswire December 2, 2025

Jazz Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference

PR Newswire November 18, 2025

Positive HERIZON-GEA-01 Phase 3 Results Support Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and Ziihera Combination Regimens as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma

PR Newswire November 17, 2025

Jazz Pharmaceuticals Showcases New Clinical and Translational Data for Modeyso(TM) (dordaviprone) in H3 K27M-mutant Diffuse Midline Glioma at SNO 2025

PR Newswire November 11, 2025

Jazz Pharmaceuticals Announces Third Quarter 2025 Financial Results and Updates 2025 Financial Guidance

PR Newswire November 5, 2025

Jazz Pharmaceuticals Appoints Ted W. Love, M.D., to its Board of Directors

PR Newswire October 28, 2025

Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 5, 2025

PR Newswire October 22, 2025

FDA Approves Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

PR Newswire October 2, 2025
View More News ››

Opinion & Analysis (NDAQ:JAZZ)

ETFs For The Next Pharma Takeover Candidates

Benzinga.com  July 28, 2015

Riding The Bull Market With These 2 Momentum ETFs

Benzinga.com  November 20, 2014
View More Opinion ››

Bullboard Posts (NDAQ:JAZZ)

RE:Cannabinoid Pharma

According to Jazz’s filings, in October 2023, it settled with Padagis US LLC and granted Padagis a license to manufacture, market, and...
alleyesonme - June 4, 2024

ENTG Extends Primary Credit Facility with BMO/Others 2+Years

For those not aware, Entourage has extended and improved it's primary credit facility with Bank of Montreal for two more years...
Wrywisdom - July 13, 2022

Cannabinoid Pharma

To my knowledge, InMed Pharma is the only company conducting clinical trials with rare cannabinoids which they can also manufacture...
Bullknit101 - September 30, 2021

Next multibagger

https://stockhouse.com/news/press-releases/2019/01/31/patient-five-cancer-free-twelve-months-after-single-anti-cancer-treatment
goregil - February 14, 2019

What happened?

Not traded? What happened to the spinoff with Conexant?
goldbug7 - January 31, 2004
View more Bullboard ››

Sparta Capital Ltd.

Sparta Capital Ltd.

Sparta Capital Ltd. engages in environment, health, and transportation businesses in Canada. It operates through Electronics ...
View More »

Podcasts